Compare MSS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSS | INTS |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 24.0M |
| IPO Year | 2023 | 2023 |
| Metric | MSS | INTS |
|---|---|---|
| Price | $0.48 | $0.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.25 | ★ $4.33 |
| AVG Volume (30 Days) | 156.0K | ★ 3.2M |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,204,523.00 | N/A |
| Revenue This Year | $4.08 | N/A |
| Revenue Next Year | $7.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 70.01 | N/A |
| 52 Week Low | $0.35 | $0.19 |
| 52 Week High | $3.96 | $3.17 |
| Indicator | MSS | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 50.79 |
| Support Level | $0.45 | $0.46 |
| Resistance Level | $0.55 | $0.54 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 48.71 | 44.78 |
Maison Solutions Inc is a fast-growing, specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly members of Asian-American communities. It is committed to providing Asian fresh produce, meat, seafood, and other daily necessities in a manner that caters to traditional Asian-American family values and cultural norms, while also accounting for the new and faster-paced lifestyle of younger generations and the diverse communities in which it operates. The company's merchandise includes fresh and, meats, seafood, and other groceries that are not found in mainstream supermarkets, including a variety of Asian vegetables and fruits such as broccoli, bitter melon, winter gourd, Shanghai baby bok choy, longan, and lychee.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.